Vertero Completes Enrollment in Phase 1b Parkinson’s Drug Study
The clinical-stage biotechnology company reported completing enrollment in a Phase 1b study of its investigational Parkinson’s treatment VT-5006.
Related stories
Dynamix to Redeem Public Shares for About $10.71 Each
Dynamix will redeem all outstanding public shares for an estimated $10.71 per share after failing to complete a business combination by its deadline.
M impact | EQUITY | Oct 29, 2026, 04:33 PM UTC
Skjern Bank Reports 9M Results, Raises Full-Year Guidance
Skjern Bank reported pretax profit of DKK 257.6 million and net interest and fee income of DKK 514.1 million for the first nine months of 2026. Loans grew 14.3% year over year.
M impact | EQUITY | Oct 29, 2026, 04:33 PM UTC
Granite Construction Reports Quarterly Results
Granite Construction reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 04:31 PM UTC
Perrigo Announces Quarterly Dividend of $0.29 Per Share
Perrigo announced a quarterly dividend of $0.29 per share.
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
Euro Stoxx Index Rises 0.73%
Euro zone blue chips are up 0.64%.
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
FTSE 100 rises 0.29%; DAX gains 1.36%
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC